Top

Published in:

Open Access 01-12-2024 | Fremanezumab | Correction

Correction: Real‑world experience with calcitonin gene‑related peptide‑targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers

Authors: Mamoru Shibata, Kazuki Fujita, Eri Hoshino, Kazushi Minami, Kenzo Koizumi, Satoshi Okada, Fumihiko Sakai

Excerpt

Correction: BMC Neurol 24, 32 (2024) …

Shibata M, Fujita K, Hoshino E, et al. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers. BMC Neurol. 2024;24:32. https://doi.org/10.1186/s12883-023-03521-y.CrossRefPubMedPubMedCentral

Title: Correction: Real‑world experience with calcitonin gene‑related peptide‑targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers
Authors: Mamoru Shibata
Kazuki Fujita
Eri Hoshino
Kazushi Minami
Kenzo Koizumi
Satoshi Okada
Fumihiko Sakai
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Fremanezumab
Galcanezumab
Migraine
Published in: BMC Neurology / Issue 1/2024
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-024-03665-5